S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
MU   39.89 (-5.16%)
GE   7.04 (-11.34%)
TSLA   481.56 (-8.10%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
GILD   72.51 (-3.01%)
PRI   84.16 (-4.88%)
DIS   94.92 (-1.74%)
Log in

NASDAQ:CLXT - Calyxt Stock Price, Forecast & News

$2.90
-0.43 (-12.91 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$2.90
Now: $2.90
$3.28
50-Day Range
$2.48
MA: $4.78
$6.72
52-Week Range
$2.40
Now: $2.90
$17.90
Volume135,822 shs
Average Volume136,878 shs
Market Capitalization$95.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
Calyxt, Inc., a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was founded in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. operates as a subsidiary of Cellectis S.A.
Read More
Calyxt logo

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorConsumer Staples
Current SymbolNASDAQ:CLXT
CUSIPN/A
Phone651-683-2807

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.30 million
Book Value$1.90 per share

Profitability

Net Income$-39,610,000.00
Net Margins-543.00%

Miscellaneous

Employees50
Market Cap$95.67 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive CLXT News and Ratings via Email

Sign-up to receive the latest news and ratings for CLXT and its competitors with MarketBeat's FREE daily newsletter.


Calyxt (NASDAQ:CLXT) Frequently Asked Questions

How has Calyxt's stock been impacted by COVID-19 (Coronavirus)?

Calyxt's stock was trading at $3.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLXT shares have decreased by 13.2% and is now trading at $2.90. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Calyxt?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calyxt in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Calyxt.

When is Calyxt's next earnings date?

Calyxt is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Calyxt.

How were Calyxt's earnings last quarter?

Calyxt Inc (NASDAQ:CLXT) released its earnings results on Thursday, March, 5th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.04. The firm had revenue of $3.76 million for the quarter. Calyxt had a negative net margin of 543.00% and a negative return on equity of 52.37%. View Calyxt's earnings history.

What guidance has Calyxt issued on next quarter's earnings?

Calyxt updated its FY 2020 Pre-Market earnings guidance on Thursday, March, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.862-15.322 million, compared to the consensus revenue estimate of $20.48 million.

What price target have analysts set for CLXT?

5 Wall Street analysts have issued 1 year target prices for Calyxt's shares. Their forecasts range from $6.00 to $16.00. On average, they expect Calyxt's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 279.3% from the stock's current price. View analysts' price targets for Calyxt.

What are Wall Street analysts saying about Calyxt stock?

Here are some recent quotes from research analysts about Calyxt stock:
  • 1. According to Zacks Investment Research, "Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company. It researches and develops seeds and food ingredients for agricultural, feed, and food applications as well as offers fat saturation and gluten reduction in soybean oil and wheat. Calyxt, Inc. is based in New Brighton, United States. " (3/12/2020)
  • 2. National Securities analysts commented, " Second Quarter Shows Progress And Growing Pains. With low and lumpy volumes in its first
    year of commercialization and weather issues reducing planted acreage from prior estimates,
    CLXT’s second quarter brought a degree of near term revenue uncertainty. OpEx also moved up
    sequentially more than we estimated. While a modest disappointment, we consider the
    improvement in distribution network and the market acceptance of the lead product to be
    encouraging and far more important to the value proposition.
     Customer Adoption Accelerates. With 20 customers currently, up from low single digits since
    the first quarter, we believe the market for both oil and meal is strong. As the company builds
    scale, we do not believe securing customers will be a meaningful hurdle. The next major bar is
    securing from consumer goods customers, which we expect over the next twelve months.
     Guilt By Association. Unwinnable tariff wars and weather challenges have dragged down Ag
    stocks this year. We believe CLXT is less exposed to these issues and can actually benefit from
    weak markets given its differentiated product offering in a commoditized space, yet the stock has
    underperformed its peers with more exposure to these variables.
     Lower Price Target, But Deep Value Opportunity. We believe the declines of 66% from its YTD
    high, and 32% in the past seven trading days alone are not justified and put the stock in deep
    value territory. Our lower price target is a reflection of adjustments to our model and assumed
    multiple, not a reflection of the value proposition which we believe remains significant." (8/8/2019)

Has Calyxt been receiving favorable news coverage?

News stories about CLXT stock have trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Calyxt earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutCalyxt.

Are investors shorting Calyxt?

Calyxt saw a decline in short interest in February. As of February 28th, there was short interest totaling 516,400 shares, a decline of 14.8% from the February 13th total of 606,300 shares. Based on an average daily trading volume, of 146,500 shares, the days-to-cover ratio is currently 3.5 days. Currently, 5.1% of the shares of the company are short sold. View Calyxt's Current Options Chain.

Who are some of Calyxt's key competitors?

What other stocks do shareholders of Calyxt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calyxt investors own include Cellectis (CLLS), Cypress Semiconductor (CY), Molecular Templates (MTEM), Advanced Micro Devices (AMD), GW Pharmaceuticals PLC- (GWPH), Intel (INTC), Netflix (NFLX), Secureworks (SCWX), AbbVie (ABBV) and Eaton (ETN).

Who are Calyxt's key executives?

Calyxt's management team includes the following people:
  • Mr. James A. Blome, Chief Exec. Officer (Age 56)
  • Dr. Daniel Voytas Ph.D., Founder & Chief Science Officer (Age 56)
  • Mr. Manoj Sahoo, Chief Commercial Officer (Age 44)
  • Mr. William F. Koschak, Chief Financial Officer (Age 50)
  • Mr. Eric Dutang, Principal Accounting Officer (Age 45)

When did Calyxt IPO?

(CLXT) raised $101 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,100,000 shares at $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

What is Calyxt's stock symbol?

Calyxt trades on the NASDAQ under the ticker symbol "CLXT."

How do I buy shares of Calyxt?

Shares of CLXT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calyxt's stock price today?

One share of CLXT stock can currently be purchased for approximately $2.90.

How big of a company is Calyxt?

Calyxt has a market capitalization of $95.67 million and generates $7.30 million in revenue each year. The company earns $-39,610,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Calyxt employs 50 workers across the globe. View additional information about Calyxt.

What is Calyxt's official website?

The official website for Calyxt is http://www.calyxt.com/.

How can I contact Calyxt?

Calyxt's mailing address is 2800 MOUNT RIDGE ROAD, ROSEVILLE MN, 55113. The company can be reached via phone at 651-683-2807 or via email at [email protected]


MarketBeat Community Rating for Calyxt (NASDAQ CLXT)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  241 (Thanks for Voting!)
Underperform Votes:  243 (Thanks for Voting!)
Total Votes:  484
MarketBeat's community ratings are surveys of what our community members think about Calyxt and other stocks. Vote "Outperform" if you believe CLXT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLXT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel